WITHDRAWN: Pegcetacoplan in the treatment of geographic atrophy.
Immunotherapy
; 2023 06 01.
Article
em En
| MEDLINE
| ID: mdl-37259853
Age-related macular degeneration is a leading cause of blindness in the elderly population worldwide. While treatments exist for the exudative (wet) form of the disease, no therapies have thus far been approved for geographic atrophy (GA), the advanced form of the non-exudative (dry) type of age-related macular degeneration. Abnormalities in the immune system are thought to be one of the major causes of GA. Pegcetacoplan is a treatment previously approved for treatment of paroxysmal nocturnal hematuria (a rare disorder that occurs when an individual's immune system attacks their own red blood cells). This article shows that when administered as an injection into the eye, pegcetacoplan shows promise as a future treatment option for patients with GA.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Immunotherapy
Assunto da revista:
ALERGIA E IMUNOLOGIA
/
TERAPEUTICA
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos
País de publicação:
Reino Unido